Growing Incidence Of Stomach Cancer To Boost The Market Driving Market Acceleration in the Gastrointestinal Stromal Tumor Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Gastrointestinal Stromal Tumor Market Size By 2025?
The market size of gastrointestinal stromal tumors has witnessed a robust growth in the previous years. The market is projected to escalate from a value of $1.28 billion in 2024 to approximately $1.37 billion by 2025, maintaining a compound annual growth rate (CAGR) of 7.2%. The augmenting growth rate during the past period is the result of factors such as higher consciousness and prompt detection, the advent of targeted treatments, improved surgical approaches, the proliferation of tailored medicine, and advancements in ancillary care.

How Big Is the Gastrointestinal Stromal Tumor Market Size Expected to Grow by 2029?
The market size for gastrointestinal stromal tumors is projected to experience robust expansion in the upcoming years, escalating to a value of $1.82 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. This surge in growth during the forecast period can be traced back to sustained research and pharmaceutical progression, an increase in healthcare that focuses on the patient, the implementation of precision medicine in clinical treatment, enhanced availability to targeted therapies, and the widening capabilities of genomic profiling. The forecast period also encompasses increasing collaboration in research and development, advancements in diagnostic technologies, cooperative research and clinical trials, intensified efforts towards early detection and diagnosis, as well as the investigation of combination therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Which Key Market Drivers Powering Gastrointestinal Stromal Tumor Market Expansion and Growth?
The gastrointestinal stromal tumor market is expected to experience growth due to an increase in stomach cancer cases. This form of cancer involves the rapid, unregulated multiplication of malignant cells within the stomach's lining. Not to be confused with stomach cancer, gastrointestinal stromal tumors (GISTs) can also develop in the stomach. The convergence of two different tumors can elevate the risk of additional cancer development in GIST patients, such as small bowel adenocarcinoma. The American Cancer Society reported in January 2024 that nearly 26,890 new cases of stomach cancer and 10,880 expected deaths in the U.S. in 2024 will constitute around 1.5% of all new cancer diagnoses. Such a surge in stomach cancer cases is the key driver of the gastrointestinal stromal tumor market's growth. Another significant factor that bolsters the gastrointestinal stromal tumor market's growth is the surging demand for precision medicine. This medical approach tailors health care decisions, interventions, and therapies to individual patient traits such as genetic and lifestyle factors. In the case of GISTs, precision medicine employs molecular profiling for mutation identification to direct therapies like imatinib, increasing treatment effectiveness and reducing side effects with customized interventions. As per a February 2023 report by the nonprofit organization Personalized Medicine Coalition (PMC), personalized medicines represented 35% of newly sanctioned NMEs in 2021. Furthermore, with 12 new approvals in 2022, personalized medicines have consistently formed at least one-fourth of new drug approvals over the preceding eight years, showcasing a drastic rise from less than 10% ten years ago. This increasing demand for precision medicine is hence contributing to the growth of the gastrointestinal stromal tumor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Gastrointestinal Stromal Tumor Market?
Leading corporations in the gastrointestinal stromal tumor market are creating innovative drugs like QINLOCK (Ripretinib) to cater to a wider consumer base, boost sales, and augment revenue. QINLOCK (Ripretinib) serves as a prescribed medication for treating advanced gastrointestinal stromal tumor (GIST). For example, according to the US Food and Drug Administration (FDA), a US federal agency, the Center for Drug Evaluation and Research (CDER) had approved 37 novel drugs in 2022, which increased to 55 drugs in 2023. In 2023, CDER categorized 20 out of these 55 novel drugs (36%) as first-in-class.

What Are the Emerging Segments in the Gastrointestinal Stromal Tumor Market?
The gastrointestinal stromal tumor market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
2) By Indication: Stomach, Small Intestine, Others Indications
3) By End-User: Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users

Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors, Other Targeted Agents
3) By Other Treatment Types: Surgery, Radiation Therapy, Clinical Trials For Novel Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp

Who Are the Global Leaders in the Gastrointestinal Stromal Tumor Market?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

Which are the Top Profitable Regional Markets for the Gastrointestinal Stromal Tumor Industry?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13248

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.